Stroke is a major cause of death and disability in the UK. Thrombolysis with alteplase has been shown to reduce disability when administered to carefully selected patients with acute ischaemic stroke. Treatment needs to be administered within 4.5 hours of stroke onset and the sooner it is given the more likely it is to be beneficial. Treatment with alteplase should only be given in units where staff are trained and experienced in the provision of stroke thrombolysis. Thrombolysis decisions involve consideration of the potential long term benefit and the risks of thrombolysis to individual patients.
Recent articles in the press and academic journals have discussed the efficacy and risks of alteplase. As there has been no licensing change for the use of alteplase in treatment of acute ischaemic stroke, BASP recommends that alteplase should continue to be used in accordance with national guidelines while we await the findings of the MHRA review.
NIHR CRN: Stroke / British Association of Stroke Physicians
Application for Portfolio Development Writing Group Funding
NIHR CRN Stroke BASP Portfolio Development Writing Group Application Template 17 Apr 2015.docx
Guidance BASP and NIHR CRN Stroke Portfolio Development Opportunity Advert Round 1.doc
BASP SPRING NEWSLETTER Newsletter Spring 2015 Final.pdf
Revalidation for Stroke Physicians' from the Clinical Standards Committee : -
ESO Summer school 2015 http://mhconsulting.cz/en-kongres-kongres_obecne-87.html
COMMITTEE ELECTION RESULTS DECEMBER 2014.docx
Standards for providing safe acute ischaemic stroke thrombectomy services are under Resources>BASP publications
IMPORTANT MESSAGE FROM THE TREASURER AND SECRETARY IS UNDER MEMBERSHIP
ESO 2015 IS UNDER EVENTS>CLINICAL TRIALS/OTHER
BASP STROKE SERVICES STANDARDS 2014 (CLINICAL STANDARDS COMMITTEE) IS UNDER